Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
Journal
JAMA Oncology
ISSN
2374-2437
Date Issued
2020
Author(s)
Kohei Shitara
Eric Van Cutsem
Yung-Jue Bang
Charles Fuchs
Lucjan Wyrwicz
Keun-Wook Lee
Iveta Kudaba
Marcelo Garrido
Hyun Cheol Chung
Jeeyun Lee
Hugo Raul Castro
Wasat Mansoor
Maria Ignez Braghiroli
Nina Karaseva
Christian Caglevic
Luis Villanueva
Eray Goekkurt
Hironaga Satake
Peter Enzinger
Maria Alsina
Al Benson
Joseph Chao
Andrew H. Ko
Zev A. Wainberg
Uma Kher
Sukrut Shah
S. Peter Kang
Josep Tabernero
Type
Resource Types::text::journal::journal article
Subjects
adult
;
aged
;
aged, 80 and over
;
antibodies, monoclonal, humanized
;
antineoplastic combined chemotherapy protocols
;
esophagogastric junction
;
female
;
humans
;
male
;
middle aged
;
stomach neoplasms
;
young adult
;
capecitabine
;
cisplatin
;
fluorouracil
;
pembrolizumab
;
antineoplastic agent
;
monoclonal antibody
;
pembrolizumab
;
adult
;
advanced cancer
;
aged
;
alopecia
;
anemia
;
antineoplastic activity
;
article
;
asthenia
;
cancer chemotherapy
;
cohort analysis
;
constipation
;
controlled study
;
decreased appetite
;
dehydration
;
diarrhea
;
dizziness
;
drug efficacy
;
drug safety
;
dry skin
;
dysgeusia
;
fatigue
;
female
;
follow up
;
human
;
hyperpigmentation
;
hypokalemia
;
hypomagnesemia
;
hypothyroidism
;
leukopenia
;
major clinical study
;
male
;
mucosa inflammation
;
nausea
;
neutropenia
;
overall survival
;
peripheral neuropathy
;
phase 3 clinical trial
;
progression free survival
;
pruritus
;
randomized controlled trial
;
rash
;
sensory neuropathy
;
side effect
;
stomach cancer
;
stomatitis
;
thrombocytopenia
;
tinnitus
;
vomiting
;
clinical trial
;
gastroesophageal junction
;
middle aged
;
mortality
;
pathology
;
stomach tumor
;
very elderly
;
young adult